SOPHiA GENETICS SA (SOPH): ANSOFF MATRIX [Dec-2025 Updated]

You're looking at SOPHiA GENETICS SA's blueprint for growth, and honestly, it's a textbook case of balancing the safe bets with the big swings. As someone who's mapped out strategies for years, I see four clear lanes here: digging deeper in the US/EU, pushing into Asia, building out the AI diagnostics, and even looking at tangential businesses like CDx kits. For instance, their Market Penetration goal to hit 20% more platform usage this year shows they aren't just resting on their laurels; they are actively trying to squeeze more value from current customers. What this matrix really gives you is a clear view of where the near-term risk lies versus the long-term payoff. Dive below to see how these four strategies-from local adoption to potential diversification-stack up for the 2025 fiscal year.

SOPHiA GENETICS SA (SOPH) - Ansoff Matrix: Market Penetration

You're looking at how SOPHiA GENETICS SA can deepen its hold in the markets it already serves, specifically with existing oncology and rare disease labs using the SOPHiA DDM platform. This is about getting more value from the customers you already have relationships with.

For existing US and European oncology labs, the penetration is showing momentum. As of September 30, 2025, SOPHiA GENETICS SA reached 488 core genomics customers, up from 462 customers at the end of Q3 2024. The U.S. market, in particular, is responding, delivering 30% year-over-year revenue growth in Q3 2025. In Europe, new adoption includes the Nice University Hospital in France, which is adopting MSK-ACCESS^® powered with SOPHiA DDM^TM in Q3 2025, and Jessa Ziekenhuis in Belgium, which adopted the platform in Q1 2025. The platform's overall analysis volume in Q3 2025 was a record 99,000 analyses, showing increased use across the installed base.

When looking at converting competitor users, the focus shifts to the value captured from new agreements. The average contract value of new signings in Q3 2025 increased by 180% year-over-year. This suggests that any aggressive pricing tiers, if offered, are being paired with larger, more comprehensive initial commitments or upsells that drive immediate, higher-value adoption rather than just small conversions.

Expanding clinical utility for existing rare disease customers is clearly happening through strategic application deployment. For instance, in Q2 2025, Igenomix, a global reproductive health and fertility reference lab, adopted SOPHiA DDM^TM for Rare and Inherited Disorder applications. Also in Q3 2025, Clinica MEDS in Chile adopted Rare Disorder applications. The broader Liquid Biopsy application, MSK-ACCESS^® powered with SOPHiA DDM^TM, had already attracted 34 leading institutions across the globe as of February 2025, indicating successful integration of new, high-value panels into existing customer workflows.

Driving higher data volume per existing client is tied directly to platform utilization and contract structure. The total analysis volume on SOPHiA DDM^TM in Q3 2025 was 99,000 analyses, which was a 9% year-over-year volume growth. For Q1 2025, the volume was 93,000 analyses, representing 11% year-over-year growth. Regarding service contract renewals, SOPHiA GENETICS SA recognizes revenue for its primary performance obligation, the delivery of analysis results, in most cases upon the issuance of the final report. However, some arrangements for software/database access are recognized on a straight-line basis over the duration of the agreement, which implies a recurring revenue component tied to the contract term, supporting sustained volume.

To drive utilization among current users, the results show organic growth in analysis volume, which is the direct output of utilization. The year-to-date analysis volume growth demonstrates the platform's increasing use within the installed base. The following table summarizes key volume and customer metrics from the first three quarters of 2025:

The growth in analysis volume, such as the 9% year-over-year increase in Q3 2025, reflects the success of efforts to increase platform utilization among existing users. The company also signed an impressive cohort of 31 new customers in Q3 2025.

• The U.S. market saw core genomics customer revenue grow over 30% in Q1 2025.
• North America revenue grew 24% year-over-year in Q2 2025.
• APAC analysis volume grew 35% year-over-year in Q3 2025.
• The total number of core genomics customers reached 488 as of September 30, 2025.

Finance: review Q4 2025 contract backlog conversion timing by next Tuesday.

SOPHiA GENETICS SA (SOPH) - Ansoff Matrix: Market Development

You're looking at how SOPHiA GENETICS SA is taking its existing SOPHiA DDM platform into new geographic territories and new customer segments. This is about expanding the reach of what you already have, which usually carries less product risk than developing something entirely new.

For the Japanese and South Korean clinical markets, the strategy involves navigating local regulatory hurdles and finding the right local champions. We saw a concrete step in Japan in October 2025 when A.D.A.M. Innovations, a leading private genetic testing company there, agreed to partner to bring liquid biopsy testing to the Japanese population using the platform. This kind of local agreement is key to unlocking these markets. While specific 2025 regulatory clearances for South Korea aren't public, the overall APAC region is showing serious traction, with analysis volume growth hitting 35% year-over-year in Q3 2025. That growth definitely suggests the groundwork for market entry is paying off in the broader region. It's a big market, and you need local expertise to win there.

Targeting large-scale national biobanks in the Middle East and Latin America relies on proving the platform's scalability. In Latin America, you already have established footholds that support this push. For instance, Dasa, the largest integrated healthcare network in Brazil, expanded its partnership in 2021, and in 2025, Seguros SURA Colombia adopted the MSK-ACCESS® solution for research initiatives. Furthermore, Bioma4me in Brazil went live on the SOPHiA DDM™ Platform in January 2024 to advance its genetic testing capabilities. These wins in Brazil and Colombia show the platform can handle complex, multi-site adoption, which is exactly what a national biobank requires. We just need to see the dollar value attached to those large-scale biobank contracts.

Adapting the platform for non-clinical research settings, specifically pharma R&D and academic consortia, is already yielding major financial results. The biggest contract in company history was signed in Q2 2025: a multi-year AI breast cancer partnership with AstraZeneca. That's a huge validation point for the platform's utility outside of routine clinical labs. Also, in November 2025, an agreement was announced with Complete Genomics to co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on their sequencing platform. This move directly targets the research infrastructure used by biopharma and academic groups, effectively expanding the addressable market without changing the core software.

Securing a major contract with a national healthcare system like the UK's NHS for population-scale genomics is a high-value target. While the first deal with the NHS was back in 2014, momentum continues, as the Royal Marsden Hospital joined as another NHS-related provider adopting SOPHiA DDM™ in Q1 2025. Population-scale projects are different; they require massive throughput and long-term commitment. We don't have a specific 2025 contract amount for a new, large-scale NHS deal, but the consistent engagement with key UK institutions suggests this remains a primary strategic avenue for market development.

Establishing a dedicated sales team for Southeast Asia is a logical follow-up to the strong performance already seen in the APAC region. As noted, Q3 2025 saw 35% year-over-year analysis volume growth in APAC, which is the highest regional growth rate reported for that quarter. This indicates a market that is rapidly adopting the technology. A dedicated team would be designed to convert this high-growth utilization into more formal, large-scale contracts, similar to the 31 new customers SOPHiA GENETICS landed globally in Q3 2025. You need boots on the ground when the market is this hot.

Here's a quick look at the key numbers underpinning this market development strategy as of late 2025:

The success in securing the largest contract in company history with AstraZeneca and the strong APAC volume growth suggest the Market Development strategy is gaining momentum. What this estimate hides is the exact revenue contribution from the newly penetrated Japanese market or the specific contract value from the NHS engagement.

Finance: draft 13-week cash view by Friday.

SOPHiA GENETICS SA (SOPH) - Ansoff Matrix: Product Development

You're looking at the engine room of SOPHiA GENETICS SA, where new products are built on the existing SOPHiA DDM™ platform. This is where the capital expenditure translates into future revenue streams, and frankly, the numbers show they are still heavily invested in building this out.

The commitment to this area is long-term; since 2011, SOPHiA GENETICS SA has invested over US$400 million to build its AI capabilities in healthcare. This investment fuels the development of new applications, like the proposed AI-powered diagnostic for early-stage Alzheimer's disease, which would expand the platform beyond its current focus areas of cancer and rare disorders.

For context on the platform's current scale, as of the third quarter of 2025, over 780 healthcare institutions use the SOPHiA DDM™ platform, analyzing over 350,000 patients per year. The platform itself processed a record 99,000 analyses in Q3 2025, marking a 9% year-over-year volume increase for that quarter.

Product development success is also seen in customer adoption of new modules, which directly relates to expanding utility, such as integrating a proprietary liquid biopsy analysis module for cancer recurrence monitoring. The MSK-ACCESS® application, which is a liquid biopsy offering, had already attracted 34 customers since its launch in Q2 2024, with the company completing implementation for a total of 15 MSK-ACCESS® customers who were set to ramp up usage throughout 2025. This focus on new applications is driving better deal value; the average contract value for new signings in Q3 2025 increased by 180% year-over-year.

The drive to onboard more users, which supports the development of models like federated learning for secure data sharing, is reflected in customer acquisition metrics. SOPHiA GENETICS SA landed 31 new core genomics customers in Q3 2025, up from 22 in Q3 2024, bringing the total core genomics customer count to 488 as of September 30, 2025.

Introducing a simplified user interface for non-genomics specialists is about broadening the user base, which is supported by the overall customer growth. The platform's utility is also expanding through strategic alliances, such as the major partnerships signed in Q3 2025 with AstraZeneca to develop an optimized next generation sequencing (NGS) solution and leverage multimodal AI Factories. This type of partnership, aimed at co-developing workflow solutions, underpins the financial outlook, with full-year 2025 revenue guidance reaffirmed in the range of $75 million to $77 million.

The financial performance of the platform, which is the base for all new products, shows an adjusted gross margin of 73.1% in Q3 2025.

The ongoing development efforts are supported by the platform's ability to scale, evidenced by the Q1 2025 milestone of passing 2 million cumulative genomic profiles analyzed since inception.

• Launch Alzheimer's application to expand beyond cancer and rare disorders.
• Integrate liquid biopsy module, building on the 34 MSK-ACCESS® customers signed by March 2025.
• Develop federated learning model to support the network of 488 core genomics customers.
• Introduce simplified UI to help non-genomics specialists use the platform.
• Partner for end-to-end workflow, building on Q3 2025 partnerships with AstraZeneca.

The Q3 2025 Adjusted EBITDA loss was $10.2 million, or an improved $8.8 million when excluding elevated Swiss social charges.

SOPHiA GENETICS SA (SOPH) - Ansoff Matrix: Diversification

You're looking at how SOPHiA GENETICS SA can move beyond its core genomics analysis business, which saw Q3 2025 revenue hit $19.5 million, up 23% year-over-year. The full-year 2025 revenue guidance is set between $75 to $77 million, representing a 15% to 18% growth rate. This diversification is about planting seeds in new, adjacent markets.

Acquire a specialized clinical trial management organization (CTMO) to offer end-to-end drug development services.

This move leverages the existing customer base, which reached 488 core genomics customers as of September 30, 2025. The company signed 31 new core genomics customers in Q3 2025 alone, with the average contract value increasing by 180% year-over-year. Integrating CTMO services could capture more of the value chain from these growing client relationships.

Develop and market proprietary, in-house developed companion diagnostic (CDx) kits alongside the data analysis service.

The global oncology companion diagnostic market was valued at USD 5.09 billion in 2024 and is projected to reach USD 8.38 billion by 2030, growing at a Compound Annual Growth Rate of 9.02% from 2025 to 2030. SOPHiA GENETICS SA has already signaled intent to develop a liquid biopsy companion diagnostic (CDx) test in Japan with a partner that has conducted over 2.8 million genetic tests to date. This aligns with the segment where products accounted for 66.14% of the market share in 2024.

Launch a direct-to-consumer (DTC) genetic testing service focused on wellness and preventative health, leveraging the AI platform.

The platform has processed a record 99,000 analyses in Q3 2025, contributing to a cumulative total of over 2 million genomic profiles analyzed since inception as of Q1 2025. A DTC offering would tap into a broader consumer base, building on the platform's proven analytical scale. To be fair, this requires a different regulatory and marketing approach than the current B2B focus.

Establish a new business unit focused on providing regulatory consulting and data submission services for pharma clients.

The current financial reality shows a Q3 2025 Net IFRS loss of $20.0 million, with an Adjusted EBITDA loss of $10.2 million (or $8.8 million excluding elevated Swiss social charges, which is a 13% year-over-year improvement). High-value, low-cost-of-goods-sold services like regulatory consulting could help bridge the gap to the targeted Adjusted EBITDA breakeven by the end of 2026, especially given the full-year Adjusted EBITDA loss guidance of $39 to $41 million.

Invest in a new therapeutic area, like infectious disease surveillance, using the core data analysis technology.

The core technology is already handling complex multimodal data, as evidenced by the platform's use across oncology and rare disorders. Expanding into infectious disease surveillance would utilize the same analytical engine that supported 488 core genomics customers at the end of Q3 2025. This is a natural extension given the platform's ability to analyze data across different diagnostic modalities.

Here's a quick math check on the current state versus the growth trajectory you're aiming for:

Diversification into these areas supports the long-term vision, especially considering the existing customer engagement levels:

• Customers using two or more applications (end of 2024): 58%
• New customers signed in Q3 2025: 31
• Year-over-year analysis volume growth (Q3 2025): 9%
• APAC analysis volume growth (Q3 2025): 35%
• NORAM analysis volume growth (Q3 2025): 26%

The technology is ready for new data types; the question is which market entry point offers the best risk-adjusted return.

Finance: draft 13-week cash view by Friday.